Movatterモバイル変換

[0]ホーム
URL:

CO5170404A1 - MELANOMAS THERAPY - Google Patents

MELANOMAS THERAPY

Info

Publication number
CO5170404A1
CO5170404A1CO00025236ACO00025236ACO5170404A1CO 5170404 A1CO5170404 A1CO 5170404A1CO 00025236 ACO00025236 ACO 00025236ACO 00025236 ACO00025236 ACO 00025236ACO 5170404 A1CO5170404 A1CO 5170404A1
Authority
CO
Colombia
Prior art keywords
patient
pegylated interferon
interferon alfa
time
melanomas
Prior art date
Application number
CO00025236A
Other languages
Spanish (es)
Inventor
Rybak Mary Eleln
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering CorpfiledCriticalSchering Corp
Publication of CO5170404A1publicationCriticalpatent/CO5170404A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

El uso de interferon alfa pegilado para la manufactura de un medicamento para el tratamiento de un paciente que tiene melanoma que ha sido removido quirúrgicamente, en donde dicho medicamento es administrado a dicho paciente en una dosis terapéuticamente eficaz de interferon alfa pegilado por un periodo de tiempo suficiente para incrementar el tiempo de supervivencia libre de progresión.El uso de interferon alfa pegilado para la manufactura de un medicamento para el tratamiento de un paciente que tiene melanoma cutáneo que ha sido removido quirúrgicamente, en donde dicho medicamento es administrado a dicho paciente en una dosis terapéuticamente eficaz de interferon alfa pegilado una vez por semana por un periodo de tiempo suficiente para incrementar el tiempo de supervivencia libre de progresión.The use of pegylated interferon alfa for the manufacture of a medicament for the treatment of a patient who has melanoma that has been surgically removed, wherein said medication is administered to said patient in a therapeutically effective dose of pegylated interferon alpha for a period of time. sufficient to increase the progression-free survival time.The use of pegylated interferon alfa for the manufacture of a medicament for the treatment of a patient who has cutaneous melanoma that has been surgically removed, wherein said medication is administered to said patient in a Therapeutically effective dose of pegylated interferon alfa once a week for a period of time sufficient to increase progression-free survival time.

CO00025236A1999-04-082000-04-06 MELANOMAS THERAPYCO5170404A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US28836699A1999-04-081999-04-08

Publications (1)

Publication NumberPublication Date
CO5170404A1true CO5170404A1 (en)2002-06-27

Family

ID=23106795

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CO00025236ACO5170404A1 (en)1999-04-082000-04-06 MELANOMAS THERAPY

Country Status (21)

CountryLink
EP (3)EP2025344B1 (en)
JP (1)JP2000319195A (en)
CN (1)CN1390132A (en)
AR (1)AR023398A1 (en)
AT (3)ATE496631T1 (en)
AU (1)AU771569B2 (en)
BR (1)BR0009646A (en)
CA (1)CA2303992A1 (en)
CO (1)CO5170404A1 (en)
CY (1)CY1108922T1 (en)
DE (3)DE60041290D1 (en)
DK (2)DK1535622T3 (en)
ES (2)ES2239954T3 (en)
HU (1)HU230057B1 (en)
MY (1)MY126763A (en)
NO (1)NO328111B1 (en)
PE (1)PE20010027A1 (en)
PT (2)PT1043026E (en)
TW (1)TWI292320B (en)
WO (1)WO2000061175A2 (en)
ZA (1)ZA200108173B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP6322413B2 (en)*2011-03-102018-05-09プロヴェクタス ファーマテック，インク． Combination of local and systemic immunomodulatory therapy for improved cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4530901A (en)1980-01-081985-07-23Biogen N.V.Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en)1982-05-062005-08-30Intermune, Inc.Manufacture and expression of large structural genes
US4492537A (en)1982-12-101985-01-08Awerkamp John BFluid-operated oil or water well pump
US4766106A (en)1985-06-261988-08-23Cetus CorporationSolubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)1985-06-261990-04-17Cetus CorporationSolubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (en)1986-03-101996-07-10エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
US5595732A (en)1991-03-251997-01-21Hoffmann-La Roche Inc.Polyethylene-protein conjugates
US5382657A (en)1992-08-261995-01-17Hoffmann-La Roche Inc.Peg-interferon conjugates
WO1995013090A1 (en)1993-11-101995-05-18Enzon, Inc.Improved interferon polymer conjugates
US5766582A (en)1994-10-111998-06-16Schering CorporationStable, aqueous alfa interferon solution formulations
JP2758154B2 (en)1995-04-061998-05-28エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
US5908621A (en)*1995-11-021999-06-01Schering CorporationPolyethylene glycol modified interferon therapy
TW517067B (en)1996-05-312003-01-11Hoffmann La RocheInterferon conjugates

Also Published As

Publication numberPublication date
WO2000061175A3 (en)2001-02-01
MY126763A (en)2006-10-31
DK1043026T3 (en)2005-07-04
PT1043026E (en)2005-09-30
AU771569B2 (en)2004-03-25
ZA200108173B (en)2003-01-06
DK1535622T3 (en)2009-04-20
AU4204600A (en)2000-11-14
EP1535622A1 (en)2005-06-01
EP1043026A3 (en)2000-12-20
EP2025344A1 (en)2009-02-18
EP1535622B1 (en)2008-12-31
DE60045591D1 (en)2011-03-10
HU230057B1 (en)2015-06-29
PE20010027A1 (en)2001-02-05
HUP0200775A3 (en)2002-09-30
BR0009646A (en)2002-02-05
EP1043026A2 (en)2000-10-11
ATE419001T1 (en)2009-01-15
CA2303992A1 (en)2000-10-08
HK1075416A1 (en)2005-12-16
NO20014852D0 (en)2001-10-05
PT1535622E (en)2009-03-19
TWI292320B (en)2008-01-11
DE60020444D1 (en)2005-07-07
ATE296639T1 (en)2005-06-15
JP2000319195A (en)2000-11-21
EP2025344B1 (en)2011-01-26
ES2319776T3 (en)2009-05-12
ATE496631T1 (en)2011-02-15
ES2239954T3 (en)2005-10-16
CN1390132A (en)2003-01-08
DE60041290D1 (en)2009-02-12
EP1043026B1 (en)2005-06-01
WO2000061175A2 (en)2000-10-19
HK1032349A1 (en)2001-07-20
CY1108922T1 (en)2014-07-02
HUP0200775A2 (en)2002-08-28
NO20014852L (en)2001-12-06
NO328111B1 (en)2009-12-07
DE60020444T2 (en)2006-05-04
AR023398A1 (en)2002-09-04

Similar Documents

PublicationPublication DateTitle
PT1173178E (en) COMPOSITION UNDERSTANDING APOMORPHINE AND SILDENAFIL AND USES THEMSELVES FOR THE TREATMENT OF ERECTILE DISFUNCTION
PT95169A (en) DOSAGE FOR THE ADMINISTRATION OF ORAL HYPOGLYCEMIC GLIPIZIDE
AR016798A1 (en) USE OF A LACTOBACILLUS CEPA FOR THE PREPARATION OF A MEDICINAL PRODUCT
NO20032027L (en) Effective anti-tumor treatments
MX9203443A (en) A DOSAGE FORM FOR THE DELAYED DELIVERY OF A PHARMACY.
AR046036A1 (en) RISEDRONATE COMPOSITIONS AND METHODS FOR USE
CO5540323A2 (en) ORAL ADMINISTRATION OF HORMONE PARATIROIDES AND CALCITONINE
AR023185A1 (en) CANCER TREATMENT IMPROVED WITH TEMOZOLOMIDE
FI20011464A0 (en) Combination therapy for the treatment of heart failure
DK1478362T3 (en) Combination therapy for acute myocardial infarction
AR029160A1 (en) THE USE OF PEGILATED INTERFERON-ALFA FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF RENAL CELL CARCINOMA, A KIT AND THE USE OF IT
CO5170404A1 (en) MELANOMAS THERAPY
CR8584A (en) PIPERAZINAS DERIVED FROM UREA FOR THE TREATMENT OF ENDOMETROSIS
AR047154A1 (en) TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL
AR109456A2 (en) USE OF ET743 FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A HUMAN PATIENT AFFECTED BY CANCER THROUGH COMBINATION THERAPY
AR016308A1 (en) USE OF PHOSPHODIESTERASE 4 INHIBITORS OR THEIR SALTS, MEDICATION FOR THE TREATMENT OF ALLERGY RHINITIS CONTAINING THE MENTIONED COMPOUNDS AND PROCEDURE TO PREPARE SUCH MEDICINAL PRODUCT.
DK1265629T3 (en) Use of growth hormone in low dose
MX9306998A (en) A THERAPEUTIC COMPOSITION OF TANDOSPIRONE AND A DOSAGE FORM TO ADMINISTER IT.
PE20010226A1 (en) USE OF PEG-MODIFIED INTERFERON FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC MYELOCYTIC LEUKEMIA

Legal Events

DateCodeTitleDescription
FCApplication refused
[8]ページ先頭
©2009-2025 Movatter.jp